688265.SH
南模生物
SSE · Healthcare · Biotechnology · CN
CNY 40.03
−5.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 432.5M | 421.0M | 381.2M | 366.5M | 303.0M |
| Cost of Revenue | 204.3M | 203.4M | 207.2M | 211.2M | 176.5M |
| Gross Profit | 228.2M | 217.6M | 174.0M | 155.3M | 126.5M |
| Operating Expenses | |||||
| R&D Expense | 87.4M | 86.7M | 75.0M | 80.2M | 65.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 54.3M | 51.0M | 53.6M | 56.4M | 57.8M |
| Selling & Marketing Expense | 61.9M | 60.5M | 58.0M | 51.1M | 37.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 209.4M | 203.0M | 191.5M | 194.9M | 159.7M |
| Cost and Expenses | 413.7M | 406.4M | 398.8M | 406.1M | 336.2M |
| Operating Income (EBIT) | 32.7M | 30.0M | 2.8M | (29.8M) | (16.4M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 31.8M | 29.1M | 2.7M | (29.9M) | (14.7M) |
| Income Tax Expense | (1.3M) | (2.3M) | (3.8M) | (9.3M) | (9.3M) |
| Bottom Line | |||||
| Net Income | 33.1M | 31.4M | 6.5M | (20.6M) | (5.4M) |
| Earnings from Cont. Ops | 33.1M | 31.4M | 6.5M | (20.6M) | (5.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 33.1M | 31.4M | 6.5M | (20.6M) | (5.4M) |
| Per Share | |||||
| Basic EPS | CN¥0.42 | CN¥0.42 | CN¥0.08 | (CN¥0.26) | (CN¥0.07) |
| Diluted EPS | CN¥0.42 | CN¥0.42 | CN¥0.08 | (CN¥0.26) | (CN¥0.07) |
| Revenue Per Share | CN¥6.33 | CN¥5.62 | CN¥4.70 | CN¥4.63 | CN¥3.93 |
| Shares | |||||
| Basic Shares Outstanding | 68.4M | 74.8M | 81.2M | 79.2M | 77.1M |
| Diluted Shares Outstanding | 68.4M | 74.8M | 81.2M | 79.2M | 77.1M |
| Profitability Metrics | |||||
| EBITDA | — | 84.4M | 57.2M | 10.7M | 14.8M |
| D&A | — | 54.5M | 54.4M | 40.5M | 31.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026